| Yukin Therapeutics–Advent France Biotechnology: investment, 201906 financing round totalling €3.3m incl founding + co-lead investor Advent France Bio |
2019-06-04 |
| Yukin Therapeutics–Medicxi: investment, 201906 financing round totalling €3.3m incl new + co-lead investor Medicxi |
2019-06-04 |
| Yukin Therapeutics–NewCap: public relations, 201906 service existent by NewCap |
2019-06-04 |
| Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi |
2019-06-04 |
| Domain Therapeutics–BPCE: investment, 201905 investment €3.5m from existing investor Seventure Partners |
2019-05-28 |
| Sensorion–Institut Pasteur: gene therapy, 201905– collab framework agreem incl license options for gene therapies for ear diseases |
2019-05-27 |
| DNA Script–France (govt): investment, 201905 financing round Series B totalling $38.5m incl new investor Bpifrance Large Venture fund |
2019-05-16 |
| DNA Script–Idinvest Partners: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Idinvest Partners |
2019-05-16 |
| DNA Script–Illumina: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Illumina Ventures |
2019-05-16 |
| DNA Script–Kurma: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Kurma Partners |
2019-05-16 |
| DNA Script–Life Sciences Partners: investment, 201905 financing round Series B totalling $38.5m incl new + lead investor LSP |
2019-05-16 |
| DNA Script–Merck (DE): investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor M Ventures |
2019-05-16 |
| DNA Script–SEVERAL: investment, 201905 financing round Series B $38.5m led by LSP |
2019-05-16 |
| DNA Script–Sofinnova: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Sofinnova Partners |
2019-05-16 |
| TreeFrog Therapeutics–Andrew Lloyd Associates: public relations, 201905 service existent by ALA |
2019-05-13 |
| TreeFrog Therapeutics–SEVERAL: investment, 201905 financing round Series A €6.5m led by XAnge + incl Galia Geston et al |
2019-05-13 |
| Therachon–Cowen: investment, 201905 existing investor Cowen |
2019-05-08 |
| Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative |
2019-05-08 |
| Therachon–Novo Group: investment, 201905 existing investor Novo Holdings |
2019-05-08 |
| Therachon–OrbiMed: investment, 201905 existing investor OrbiMed |
2019-05-08 |
| Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures |
2019-05-08 |
| Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program |
2019-05-08 |
| Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC |
2019-05-08 |
| Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures |
2019-05-08 |
| AstraZeneca–Transgene: cancer immunotherapy, 201905– collab + license option $10m upfront developm armed oncolytic vaccinia viruses using Invir.IO |
2019-05-02 |
| Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson |
2019-05-02 |
| Alentis Therapeutics–Bellevue: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BB Pureos Bioventures |
2019-04-30 |
| Alentis Therapeutics–BioMedPartners: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BioMedPartners |
2019-04-30 |
| Alentis Therapeutics–France (govt): investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Bpifrance |
2019-04-30 |
| Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif |
2019-04-30 |
| Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq |
2019-04-30 |
| Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures |
2019-04-30 |
| JnJ–Iktos: drug discovery services, 201904– collab using AI technology for small molecule drug discovery projects Janssen |
2019-04-29 |
| Genecast (CN)–HalioDx: cancer test, 201904– distribution excl of Immunoscore Colon Assay in China by Genecast |
2019-04-19 |
| Theranexus–IRISA (FR): bioinformatics, 210904– collab using AI for targeting neuroglial interactions for drug discovery with Dyliss Group |
2019-04-09 |
| AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France |
2019-04-03 |
| AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF |
2019-04-03 |
| AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes |
2019-04-03 |
| AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax |
2019-04-03 |
| AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology |
2019-04-03 |
| AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures |
2019-04-03 |
| Karuna–Sofinnova: investment, 201903–201904 financing round Series B totalling $80m incl $12m from new investor Sofinnova Investments |
2019-04-01 |
| Cellnovo–NONE: investment, 201903 in administration |
2019-03-28 |
| Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA |
2019-03-28 |
| Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA |
2019-03-28 |
| Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners |
2019-03-28 |
| H4Orphan Pharma–Cerenis: investment, 201903–201904 excl merger negotations w Cerenis owning 59% of combined company TERMINATED 4/19 |
2019-03-27 |
| Pierre Fabre–Institut Curie: cancer immunotherapy, 201903– collab extension I-O drug target discovery with IRPF |
2019-03-21 |
| Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) |
2019-03-20 |
| Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares |
2019-03-20 |
| Merck (DE)–Iktos: drug discovery services, 201903– collab using AI technology for small molecule drug discovery projects |
2019-03-14 |
| BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m |
2019-03-05 |
| Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB |
2019-03-05 |
| Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| TreeFrog Therapeutics–SEVERAL: grant, 201903 non-dilutive funding €600k from Nouvelle-Aquitaine Region + Bpifrance + French Ministry of Research |
2019-03-01 |
| Genfit–SEVERAL: investment, 201902–201903 private placement €9m with 500k ordinary shares at €18/share in Europe + outside North America |
2019-02-27 |
| Genfit–SEVERAL: investment, 201902–201903 US IPO $125m with 6.15m ADSs at $20.32/ADS at Nasdaq Global Select Market |
2019-02-27 |
| Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures |
2019-02-21 |
| BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund |
2019-02-20 |
| BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al |
2019-02-20 |
| BPCE–Yucatan: public relations, 201902 service existent media relations for Seventure Parnters in France by Agence Yucatan |
2019-02-20 |
| Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate |
2019-02-14 |
| Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals |
2019-02-14 |
| CiToxLab–Charles River: investment, 201902– acquisition $448m in cash BINDING OFFER SIGNED |
2019-02-13 |
| Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan |
2019-02-11 |
| Grey Wolf Therapeutics–Canaan Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan |
2019-02-11 |
| Grey Wolf Therapeutics–SEVERAL: investment, 201902 financing round Series A £10m with Andera Partners + Canaan |
2019-02-11 |
| Invisible Sentinel–Mérieux: investment, 201902 acquisition $75m in cash by bioMérieux |
2019-02-07 |
| Axial Biotherapeutics–BPCE: investment, 201902 financing round Series B totalling $25m incl new investor Seventure Partners |
2019-02-01 |
| Axial Biotherapeutics–SEVERAL: investment, 201902 financing round Series B $25m incl Seventure Partners |
2019-02-01 |
| Pharnext–CB Lux: investment, 201901 private placement €15m with 1.02m new shares at €14.7/share to CB Lux raising share from 21.12% to 27.79% |
2019-01-23 |
| ImaBiotech–Metabrain Research: preclinical research services, 201901– collab strategic partnership ADMET services in preclin metabolic disease models |
2019-01-17 |
| ImaBiotech–OCR (FR): preclinical research services, 201901– collab strategic partnership oncology research in pet tumors using bioanalytical imaging |
2019-01-17 |
| Nanobiotix–RooneyPartners: public relations, 201901 service existent US media relations by RooneyPartners |
2019-01-16 |
| Nanobiotix–SEVERAL: investment, 201901– filing of Form F-1 for registered public offering of shares + ADSs in US conditions to be determined later |
2019-01-16 |
| Sanofi–Biomunex: antibody technology, 201901– license €na to use BiXAb technology to generate + develop bi- + multi-specific antibodies |
2019-01-15 |
| Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo |
2019-01-04 |
| Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital |
2019-01-04 |
| Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation |
2019-01-04 |
| Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners |
2019-01-04 |
| Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP |
2019-01-04 |
| MycoTechnology–SEVERAL: investment, 201901 financing round Series C $30m |
2019-01-01 |
| Vedanta Biosciences–BMS: investment, 201812 financing round Series C totalling $27m incl new investor BMS |
2018-12-24 |
| Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners |
2018-12-24 |
| Vedanta Biosciences–Gates Foundation: investment, 201812 financing round Series C totalling $27m incl new investor Gates Foundation |
2018-12-24 |
| Vedanta Biosciences–Invesco: investment, 201812 financing round Series C totalling $27m incl existing investor Invesco Asset Management |
2018-12-24 |
| Vedanta Biosciences–PureTech Health: investment, 201812 financing round Series C totalling $27m incl existing investor PureTech Health |
2018-12-24 |
| Vedanta Biosciences–Rock Springs Capital: investment, 201812 financing round Series C totalling $27m incl existing investor Rock Springs Capital |
2018-12-24 |
| Vedanta Biosciences–SEVERAL: investment, 201812 financing round Series C $27m Gates + BMS + Rock Springs Capital + Invesco + Seventure + PureTech |
2018-12-24 |
| France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis |
2018-12-20 |
| Carmat–EU (govt): credit, 201812– EFSI €30m loan from EIB to move artificial heart towards marketing |
2018-12-17 |
| Kurma–France (govt): investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest |
2018-12-14 |
| Kurma–Idinvest Partners: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest |
2018-12-14 |
| Kurma–NewCap: public relations, 201812 service existent by NewCap |
2018-12-14 |
| Kurma–Servier: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest |
2018-12-14 |
| Kurma–SEVERAL: investment, 201812 first closing of Kurma Biofund III with target for final closing of €150m |
2018-12-14 |
| Pharvaris–Kurma: investment, 201812 existing founding investor Kurma Biofund II |
2018-12-14 |
![[LSF] Life-Sciences-France.com - The French Life Sciences Web Portal](/images/basics/lsf-life-sciences-france-portal-logo-2019.png){kind=logo}
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lsus-life-sciences-usa-com-beta.jpg)
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
